Developing automated systems to evolve biomolecules for medical use
ePACE: automation platforms for adaptable and scalable continuous evolution of biomolecules with therapeutic potential
['FUNDING_R01'] · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · NIH-11083149
This study is working on new technology to quickly create helpful biomolecules that could lead to better treatments for cancer and genetic disorders, aiming to improve care for patients who need it most.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11083149 on ClinicalTrials.gov |
What this research studies
This research focuses on creating advanced automated platforms that can continuously evolve biomolecules, which are essential for various medical applications, including cancer treatment and gene editing. By utilizing a method called Phage-Assisted Continuous Evolution (PACE) combined with a customizable culture system, the team aims to enhance the speed and efficiency of generating new biomolecules. Patients may benefit from the development of innovative therapies that target unmet medical needs, particularly in cancer immunotherapy and genetic disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that could be treated with novel biomolecules, such as cancer or genetic disorders requiring advanced therapies.
Not a fit: Patients with conditions that do not involve biomolecular therapies or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective therapies for cancer and genetic diseases.
How similar studies have performed: Other research has shown promise with similar continuous evolution techniques, indicating a potential for significant advancements in therapeutic development.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KHALIL, AHMAD SAMIR — BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- Study coordinator: KHALIL, AHMAD SAMIR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy